{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T21:51:49Z","timestamp":1770328309872,"version":"3.49.0"},"update-to":[{"DOI":"10.1371\/journal.pntd.0013597","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000}}],"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bem-Te-Vi Diversidade","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"Nationale Postcode Loterij","award":["-"],"award-info":[{"award-number":["-"]}]},{"DOI":"10.13039\/100008196","name":"M\u00e9decins Sans Fronti\u00e8res","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/100008196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007729","name":"Dutch Ministry of Foreign Affairs","doi-asserted-by":"crossref","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/501100007729","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Federal Ministry of Education and Research (BMBF), Germany","award":["-"],"award-info":[{"award-number":["-"]}]},{"DOI":"10.13039\/100009131","name":"Swiss Agency for Development and Cooperation","doi-asserted-by":"crossref","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/100009131","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000278","name":"Department for International Development, UK Government","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/501100000278","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Infection with the protozoan\n                      <jats:italic>Trypanosoma cruzi<\/jats:italic>\n                      leads to Chagas disease, a neglected tropical disease with potentially serious complications. Infection commonly takes place in childhood which can lead, without timely diagnosis and accurate treatment, to severe cardiac events and early mortality. For many years there were no pediatric formulations. Currently, there are two very effective treatments. Nevertheless, new drugs and shorter treatments are desirable. Therefore, the aim of this report is to provide a target product profile (TPP) to guide the development of pediatric formulations of new drugs for the treatment of children with Chagas disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A review of the relevant literature, focusing on the therapeutic options available for pediatric Chagas disease, was undertaken prior to setting up a TPP working group of recognized leaders in the field. After several drafts, the TPP was established through a consensus agreement by the group. For each attribute, essential and ideal requirements were defined, which specified the required TPP performance and use characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The TPP for the development of formulations of new drugs for treatment of children with\n                      <jats:italic>T. cruzi<\/jats:italic>\n                      infection includes 15 different attributes. The target population was defined as newborns to adolescents up to 18 years. The essential indication for the target product would cover acute\/congenital and chronic\n                      <jats:italic>T. cruzi<\/jats:italic>\n                      infection; the ideal indication would include chronic indeterminate, congenital and\/or acute vector-borne\n                      <jats:italic>T. cruzi<\/jats:italic>\n                      infection; people who are immunosuppressed, and pregnant and breastfeeding women. An age-appropriate drug formulation, acceptable palatability, dose, and ease of administration were considered to be particularly important for children.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The TPP provides guidance for essential and ideal characteristics of formulations of new drugs for the treatment of children with\n                      <jats:italic>T. cruzi<\/jats:italic>\n                      infection.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pntd.0013597","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:41:33Z","timestamp":1767984093000},"page":"e0013597","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Target product profile for the development of pediatric formulations of new drugs for the treatment of children with T. cruzi infection"],"prefix":"10.1371","volume":"20","author":[{"given":"Colin","family":"Forsyth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Facundo","family":"Garcia-Bournissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Moscatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samanta","family":"Moroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Pereiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourdes","family":"Ortiz-Daza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira-Idalia Hern\u00e1ndez","family":"Cuevas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freddy","family":"Tinajeros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tayn\u00e1","family":"Marques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Marchiol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Herazo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Seu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Altcheh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4237-1075","authenticated-orcid":true,"given":"Mar\u00eda-Jes\u00fas","family":"Pinazo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"issue":"1","key":"pntd.0013597.ref001","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00023-19","article-title":"Chagas Disease in the United States: a Public Health Approach","volume":"33","author":"C Bern","year":"2019","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"pntd.0013597.ref002","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.semdp.2019.04.008","article-title":"Chagas disease as example of a reemerging parasite","volume":"36","author":"J Guarner","year":"2019","journal-title":"Semin Diagn Pathol"},{"issue":"3","key":"pntd.0013597.ref003","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4269\/ajtmh.17-0657","article-title":"Parasite-Vector Interaction of Chagas Disease: A Mini-Review","volume":"98","author":"ABB de Oliveira","year":"2018","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"pntd.0013597.ref004","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12916-023-02885-9","article-title":"Putting Chagas disease on the global health agenda","volume":"21","author":"BMC Medicine","year":"2023","journal-title":"BMC Med"},{"issue":"2","key":"pntd.0013597.ref005","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00152-21","article-title":"Worldwide Control and Management of Chagas Disease in a New Era of Globalization: a Close Look at Congenital Trypanosoma cruzi Infection","volume":"35","author":"A Abras","year":"2022","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"pntd.0013597.ref006","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1590\/0074-02760140347","article-title":"Prevention of congenital Chagas through treatment of girls and women of childbearing age","volume":"110","author":"G Moscatelli","year":"2015","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"1","key":"pntd.0013597.ref007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011895","article-title":"Efficacy of short-course treatment for prevention of congenital transmission of Chagas disease: A retrospective cohort study","volume":"18","author":"G Moscatelli","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"issue":"9","key":"pntd.0013597.ref008","article-title":"Prevention of congenital chagas disease by trypanocide treatment in women of reproductive age: A meta-analysis of observational studies","volume":"18","author":"FCAd Moraes","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0013597.ref009","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.actatropica.2017.07.004","article-title":"Prevention of congenital Chagas disease by Benznidazole treatment in reproductive-age women. An observational study","volume":"174","author":"MG \u00c1lvarez","year":"2017","journal-title":"Acta Trop"},{"issue":"11","key":"pntd.0013597.ref010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003312","article-title":"Trypanocide treatment of women infected with Trypanosoma cruzi and its effect on preventing congenital Chagas","volume":"8","author":"DL Fabbro","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0013597.ref011","author":"WHO","year":"2024"},{"issue":"2","key":"pntd.0013597.ref012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006226","article-title":"A novel antibody surrogate biomarker to monitor parasite persistence in Trypanosoma cruzi-infected patients","volume":"12","author":"M Zrein","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"pntd.0013597.ref013","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/bcp.14700","article-title":"Review of pharmacological options for the treatment of Chagas disease","volume":"88","author":"F Lascano","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"pntd.0013597.ref014","article-title":"Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection)","volume":"12","author":"M Vallejo","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"pntd.0013597.ref015","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s11886-024-02113-7","article-title":"Chagas Disease: Epidemiology, Diagnosis, and Treatment","volume":"26","author":"MC Swett","year":"2024","journal-title":"Curr Cardiol Rep"},{"issue":"5","key":"pntd.0013597.ref016","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/14787210.2021.1834849","article-title":"Benznidazole for the treatment of Chagas disease","volume":"19","author":"I Losada Galv\u00e1n","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"3","key":"pntd.0013597.ref017","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/14787210.2019.1577731","article-title":"Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America","volume":"17","author":"J Alonso-Padilla","year":"2019","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"5","key":"pntd.0013597.ref018","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2471\/BLT.22.289521","article-title":"WHO target product profiles to shape global research and development","volume":"101","author":"SC Charnaud","year":"2023","journal-title":"Bull World Health Organ"},{"issue":"3","key":"pntd.0013597.ref019","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrd.2016.264","article-title":"Regulatory watch: The target product profile as a tool for regulatory communication: advantageous but underused","volume":"16","author":"A Tyndall","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"pntd.0013597.ref020","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40801-020-00203-w","article-title":"Using Real-World Data to Predict Clinical and Economic Benefits of a Future Drug Based on its Target Product Profile","volume":"7","author":"C Gerlinger","year":"2020","journal-title":"Drugs Real World Outcomes"},{"issue":"6","key":"pntd.0013597.ref021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003697","article-title":"Target Product Profile (TPP) for Chagas Disease Point-of-Care Diagnosis and Assessment of Response to Treatment","volume":"9","author":"AI Porr\u00e1s","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"pntd.0013597.ref022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008035","article-title":"Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus","volume":"14","author":"J Alonso-Padilla","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0013597.ref023","author":"(DNDi) DfNDi","year":"2017"},{"issue":"2","key":"pntd.0013597.ref024","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.clp.2021.03.013","article-title":"Chagas Disease: Implementation of Screening to Benefit Mother and Infant","volume":"48","author":"MS Edwards","year":"2021","journal-title":"Clin Perinatol"},{"issue":"18","key":"pntd.0013597.ref025","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1001\/jama.298.18.2171","article-title":"Evaluation and treatment of chagas disease in the United States: a systematic review","volume":"298","author":"C Bern","year":"2007","journal-title":"JAMA"},{"key":"pntd.0013597.ref026","article-title":"Perspectives for a new drug candidate for Chagas disease therapy","volume":"117","author":"NC Soeiro M de","year":"2022","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"5","key":"pntd.0013597.ref027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002907","article-title":"Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults","volume":"8","author":"J Altcheh","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0013597.ref028","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2010-1172","article-title":"Adverse events after the use of benznidazole in infants and children with Chagas disease","volume":"127","author":"J Altcheh","year":"2011","journal-title":"Pediatrics"},{"issue":"1","key":"pntd.0013597.ref029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008912","article-title":"Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO)","volume":"15","author":"J Altcheh","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"pntd.0013597.ref030","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01193-22","article-title":"Efficacy and Safety of Nifurtimox in Pediatric Patients with Chagas Disease: Results at 4-Year Follow-Up in a Prospective, Historically Controlled Study (CHICO SECURE)","volume":"67","author":"J Altcheh","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"pntd.0013597.ref031","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/ijgo.14994","article-title":"Mother-to-child Chagas disease transmission: The challenge of detection and prevention in areas without the risk of vectorial transmission","volume":"164","author":"S Palacios Gil-Antu\u00f1ano","year":"2024","journal-title":"Int J Gynaecol Obstet"},{"issue":"5","key":"pntd.0013597.ref032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010850","article-title":"Population pharmacokinetics of benznidazole in neonates, infants and children using a new pediatric formulation","volume":"17","author":"J Altcheh","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0013597.ref033","author":"DNDi","year":"2021"},{"key":"pntd.0013597.ref034","doi-asserted-by":"crossref","first-page":"106219","DOI":"10.1016\/j.actatropica.2021.106219","article-title":"On-site experience of a project to increase access to diagnosis and treatment of Chagas disease in high-risk endemic areas of Colombia","volume":"226","author":"R Herazo","year":"2022","journal-title":"Acta Trop"},{"key":"pntd.0013597.ref035","article-title":"Critical analysis of Chagas disease treatment in different countries","volume":"117","author":"SNS Mendes F de","year":"2022","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"6","key":"pntd.0013597.ref036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008398","article-title":"Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole","volume":"14","author":"K Yoshioka","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0013597.ref037","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/tropicalmed6030128","article-title":"A Rapid Review on the Efficacy and Safety of Pharmacological Treatments for Chagas Disease","volume":"6","author":"CJ Malone","year":"2021","journal-title":"Trop Med Infect Dis"},{"issue":"10","key":"pntd.0013597.ref038","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.3390\/pharmaceutics15102431","article-title":"Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies","volume":"15","author":"C Domingues","year":"2023","journal-title":"Pharmaceutics"},{"issue":"11","key":"pntd.0013597.ref039","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3390\/ph15111331","article-title":"Overcoming Challenges in Pediatric Formulation with a Patient-Centric Design Approach: A Proof-of-Concept Study on the Design of an Oral Solution of a Bitter Drug","volume":"15","author":"JDN Ogbonna","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"pntd.0013597.ref040","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3390\/pharmaceutics14030473","article-title":"Assessing the Appropriateness of Formulations on the WHO Model List of Essential Medicines for Children: Development of a Paediatric Quality Target Product Profile Tool","volume":"14","author":"J Walsh","year":"2022","journal-title":"Pharmaceutics"},{"issue":"2","key":"pntd.0013597.ref041","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/bcp.15148","article-title":"Twice neglected? Neglected diseases in neglected populations","volume":"88","author":"ED Weld","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"pntd.0013597.ref042","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1128\/JCM.00142-16","article-title":"Serological Diagnosis of Chronic Chagas Disease: Is It Time for a Change?","volume":"54","author":"A Abras","year":"2016","journal-title":"J Clin Microbiol"},{"issue":"1","key":"pntd.0013597.ref043","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40249-023-01143-7","article-title":"Molecular diagnosis of Chagas disease: a systematic review and meta-analysis","volume":"12","author":"G Pascual-V\u00e1zquez","year":"2023","journal-title":"Infect Dis Poverty"},{"issue":"5","key":"pntd.0013597.ref044","article-title":"Parasitemia Levels in Trypanosoma cruzi Infection in Spain, an Area Where the Disease Is Not Endemic: Trends by Different Molecular Approaches","volume":"10","author":"MD Flores-Chavez","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"8","key":"pntd.0013597.ref045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007668","article-title":"Longitudinal follow up of serological response in children treated for Chagas disease","volume":"13","author":"G Moscatelli","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"pntd.0013597.ref046","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02021-21","article-title":"Effectiveness of Nifurtimox in the Treatment of Chagas Disease: a Long-Term Retrospective Cohort Study in Children and Adults","volume":"66","author":"N Falk","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"pntd.0013597.ref047","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1111\/bcp.16214","article-title":"Adverse events associated with benznidazole treatment for Chagas disease in children and adults","volume":"90","author":"CV Cruz","year":"2024","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"pntd.0013597.ref048","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007647","article-title":"Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease","volume":"13","author":"S Moroni","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0013597.ref049","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/archdischild-2014-306358","article-title":"Limited infant exposure to benznidazole through breast milk during maternal treatment for Chagas disease","volume":"100","author":"F Garc\u00eda-Bournissen","year":"2015","journal-title":"Arch Dis Child"},{"issue":"3","key":"pntd.0013597.ref050","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2471\/BLT.16.171967","article-title":"Medicines for children: flexible solid oral formulations","volume":"95","author":"ES Orubu","year":"2017","journal-title":"Bull World Health Organ"},{"issue":"6","key":"pntd.0013597.ref051","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/17460441.2024.2349155","article-title":"New drug discovery strategies for the treatment of benznidazole-resistance in Trypanosoma cruzi, the causative agent of Chagas disease","volume":"19","author":"SMF Murta","year":"2024","journal-title":"Expert Opin Drug Discov"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0013597","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0013597","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T23:26:15Z","timestamp":1770247575000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0013597"}},"subtitle":[],"editor":[{"given":"Pierre","family":"Buekens","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0013597","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]}}}